YMRC
RPRX icon

Yorktown Management & Research Company’s Royalty Pharma RPRX Stock Holding History

Yorktown Management & Research Company’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,370
Closed -$212K – 209
2022
Q4 		$212K Hold
5,370
– – 0.26% 173
2022
Q3 		$216K Hold
5,370
– – 0.28% 166
2022
Q2 		$226K Buy
+5,370
New +$220K 0.29% 156

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Yorktown Management & Research Company's RPRX Position: Q1 2023 in Review

Yorktown Management & Research Company sold out of Royalty Pharma (RPRX) in Q1 2023, closing a stake of 5,370 shares — an estimated $212K sold.

Yorktown Management & Research Company first reported a position in RPRX in Q2 2022 and held it in 3 quarters. The position peaked at $226K in Q2 2022. 335 funds tracked by Wall St. Rank hold RPRX as of Q1 2023.

  • Yorktown Management & Research Company reported no remaining Royalty Pharma position as of Q1 2023 after selling out during the quarter.
  • Yorktown Management & Research Company sold 5,370 Royalty Pharma shares in Q1 2023, an estimated $212K.
  • Yorktown Management & Research Company first reported a position in Royalty Pharma in Q2 2022 and held it in 3 quarters.
  • Yorktown Management & Research Company's Royalty Pharma position peaked at $226K in Q2 2022.
  • 335 funds tracked by Wall St. Rank held Royalty Pharma as of Q1 2023.

Based on Yorktown Management & Research Company's 13F filing for Q1 2023, filed 21 Apr 2023.